FATE
VENTE TOTALE: 43 947 titres (~108 100,83 $ US)
- Insiders
- Valamehr Bahram
- Total bought
- —
- Total sold
- $108,101
- Last activity
- 2026-08-04
- Last synced
-
2026-08-10 09:45:27
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-05
FATE presents a critically weak fundamental profile — severe cash burn, deeply negative profitability metrics (ROA, ROE, ROIC), and meaningful insolvency risk — that the moderate liquidity score (65) cannot offset.
The first sentence of the analysis written for FATE on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -94.1% | -769.6% | -147.4% | 85.7% | 89.5% | |
| Ebit Margin | -2051.1% | -1434.5% | -253.3% | -292.5% | -379.9% | |
| Ebitda Margin | -1911.2% | -1295.4% | -224.5% | -278.3% | -369.4% | |
| Operating Profit Margin | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% | |
| Pretax Profit Margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | |
| Continuous Operations Profit Margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | |
| Net Profit Margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | |
| Bottom Line Profit Margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | |
| Current Ratio | 5.786 | 7.578 | 8.481 | 4.402 | 7.793 | |
| Quick Ratio | 5.786 | 7.578 | 8.481 | 4.402 | 7.793 | |
| Solvency Ratio | -1.137 | -1.372 | -1.035 | -1.209 | -0.850 | |
| Cash Ratio | 1.293 | 0.936 | 1.071 | 0.538 | 1.643 | |
| Price To Earnings Ratio | -0.854 | -1.006 | -2.280 | -3.467 | -26.121 | |
| Price To Earnings Growth Ratio | 0.029 | 0.000 | 0.052 | -0.116 | -3.918 | |
| Forward Price To Earnings Growth Ratio | 0.029 | 0.000 | 0.052 | -0.116 | -3.918 | |
| Price To Earnings Diluted Ratio | -0.854 | -1.006 | -2.280 | -3.467 | -26.121 | |
| Price To Earnings Diluted Growth Ratio | 0.029 | 0.000 | 0.052 | -0.116 | -3.918 | |
| Price To Book Ratio | 0.563 | 0.589 | 0.999 | 2.019 | 8.166 | |
| Price To Sales Ratio | 17.563 | 13.761 | 5.793 | 10.145 | 99.267 | |
| Price To Free Cash Flow Ratio | -1.042 | -1.518 | -2.659 | -3.443 | -25.957 | |
| Price To Operating Cash Flow Ratio | -1.100 | -1.527 | -2.783 | -3.936 | -34.037 | |
| Debt To Assets Ratio | 0.244 | 0.193 | 0.205 | 0.155 | 0.125 | |
| Debt To Equity Ratio | 0.376 | 0.268 | 0.281 | 0.226 | 0.169 | |
| Debt To Capital Ratio | 0.273 | 0.211 | 0.219 | 0.184 | 0.145 | |
| Long Term Debt To Capital Ratio | 0.261 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.539 | 1.383 | 1.374 | 1.458 | 1.357 | |
| Working Capital Turnover Ratio | 0.031 | 0.050 | 0.187 | 0.205 | 0.116 | |
| Operating Cash Flow Ratio | -2.941 | -3.190 | -3.383 | -2.176 | -2.004 | |
| Operating Cash Flow Sales Ratio | -15.962 | -9.014 | -2.082 | -2.577 | -2.916 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | 1.006 | 1.047 | 1.143 | 1.311 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -23.097 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -21.416 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.363 | -1.441 | -1.277 | -2.270 | -1.419 | |
| Capital Expenditure Coverage Ratio | -17.820 | -168.321 | -21.496 | -6.979 | -3.212 | |
| Dividend Paid And Capex Coverage Ratio | -17.820 | -168.321 | -21.496 | -6.979 | -3.212 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.165 | -1.341 | -3.013 | -3.825 | -26.781 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -94.1% | ▲675.5% | ▲73.0% |
| Ebit Margin | -2051.1% | ▼-616.6% | ▼-1168.8% |
| Ebitda Margin | -1911.2% | ▼-615.8% | ▼-1095.5% |
| Operating Profit Margin | -2222.4% | ▼-679.8% | ▼-1267.7% |
| Pretax Profit Margin | -2051.1% | ▼-684.6% | ▼-1182.4% |
| Continuous Operations Profit Margin | -2051.1% | ▼-684.6% | ▼-1182.4% |
| Net Profit Margin | -2051.1% | ▼-684.6% | ▼-1182.4% |
| Bottom Line Profit Margin | -2051.1% | ▼-684.6% | ▼-1182.4% |
| Current Ratio | 5.786 | ▼-1.792 | ▼-1.022 |
| Quick Ratio | 5.786 | ▼-1.792 | ▼-1.022 |
| Solvency Ratio | -1.137 | ▲0.235 | ▼-0.016 |
| Cash Ratio | 1.293 | ▲0.357 | ▲0.197 |
| Price To Earnings Ratio | -0.854 | ▲0.152 | ▲5.891 |
| Price To Earnings Growth Ratio | 0.029 | ▲0.029 | ▲0.819 |
| Forward Price To Earnings Growth Ratio | 0.029 | ▲0.029 | ▲0.819 |
| Price To Earnings Diluted Ratio | -0.854 | ▲0.152 | ▲5.891 |
| Price To Earnings Diluted Growth Ratio | 0.029 | ▲0.029 | ▲0.819 |
| Price To Book Ratio | 0.563 | ▼-0.025 | ▼-1.904 |
| Price To Sales Ratio | 17.563 | ▲3.802 | ▼-11.743 |
| Price To Free Cash Flow Ratio | -1.042 | ▲0.476 | ▲5.882 |
| Price To Operating Cash Flow Ratio | -1.100 | ▲0.426 | ▲7.576 |
| Debt To Assets Ratio | 0.244 | ▲0.051 | ▲0.060 |
| Debt To Equity Ratio | 0.376 | ▲0.108 | ▲0.112 |
| Debt To Capital Ratio | 0.273 | ▲0.062 | ▲0.067 |
| Long Term Debt To Capital Ratio | 0.261 | ▲0.261 | ▲0.209 |
| Financial Leverage Ratio | 1.539 | ▲0.157 | ▲0.117 |
| Working Capital Turnover Ratio | 0.031 | ▼-0.019 | ▼-0.087 |
| Operating Cash Flow Ratio | -2.941 | ▲0.249 | ▼-0.202 |
| Operating Cash Flow Sales Ratio | -15.962 | ▼-6.948 | ▼-9.452 |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | ▲0.050 | ▼-0.057 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲4.619 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲4.283 |
| Operating Cash Flow Coverage Ratio | -1.363 | ▲0.078 | ▲0.191 |
| Capital Expenditure Coverage Ratio | -17.820 | ▲150.500 | ▲25.745 |
| Dividend Paid And Capex Coverage Ratio | -17.820 | ▲150.500 | ▲25.745 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.165 | ▲0.176 | ▲6.060 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $116.7M | $187.6M | $368.1M | $977.0M | $5.54B | |
| Enterprise value | $147.9M | $236.8M | $429.7M | $1.02B | $5.52B | |
| EV / Sales | 22.26x | 17.37x | 6.76x | 10.64x | 98.93x | |
| EV / Op. cash flow | -1.40x | -1.93x | -3.25x | -4.13x | -33.92x | |
| EV / Free cash flow | -1.32x | -1.92x | -3.10x | -3.61x | -25.87x | |
| EV / EBITDA | -1.17x | -1.34x | -3.01x | -3.83x | -26.78x | |
| Net debt / EBITDA | -0.25x | -0.28x | -0.43x | -0.18x | 0.09x | |
| Current ratio | 5.79x | 7.58x | 8.48x | 4.40x | 7.79x | |
| Income quality | 0.78x | 0.66x | 0.82x | 0.88x | 0.77x | |
| Graham net-net | $1 | $1 | $2 | $3 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 95.3% | 100.0% | 100.0% | 100.0% | |
| Working capital | $172.6M | $253.4M | $292.4M | $388.0M | $552.1M | |
| Invested capital | $271.2M | $364.3M | $451.0M | $454.1M | $714.4M | |
| Return on assets | -42.7% | -42.3% | -31.8% | -39.9% | -23.0% | |
| Operating ROA | -38.9% | -44.4% | -31.4% | -37.9% | -28.1% | |
| Return on tangible assets | -42.7% | -42.3% | -31.8% | -39.9% | -23.0% | |
| Return on equity | -65.8% | -58.4% | -43.7% | -58.2% | -31.3% | |
| Return on invested capital | -51.4% | -51.3% | -40.3% | -51.6% | -25.7% | |
| Return on capital employed | -52.2% | -52.3% | -40.8% | -52.1% | -25.8% | |
| Earnings yield | -116.8% | -99.3% | -43.7% | -28.8% | -3.8% | |
| Free cash flow yield | -96.0% | -65.9% | -37.6% | -29.0% | -3.9% | |
| Capex / Op. cash flow | -5.6% | -0.6% | -4.7% | -14.3% | -31.1% | |
| Capex / Depreciation | 64.0% | 3.8% | 33.7% | 258.5% | 866.7% | |
| Capex / Sales | 89.6% | 5.4% | 9.7% | 36.9% | 90.8% | |
| SG&A / Sales | 700.0% | 664.9% | 152.5% | 87.5% | 102.6% | |
| R&D / Sales | 1622.5% | 990.4% | 271.7% | 332.8% | 385.9% | |
| Stock comp / Sales | 375.0% | 304.4% | 68.4% | 81.8% | 97.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 50d | 95d | 10d | 146d | 57d | |
| Days payables outstanding | 75d | 29d | 11d | 219d | 537d | |
| Operating cycle | 50d | 95d | 10d | 146d | 57d | |
| Cash conversion cycle | -25d | 66d | -0d | -73d | -481d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-37.8%EV / Sales ▲+28.1%EV / EBITDA ▲+13.1%EV / Op. cash flow ▲+0.532Earnings yield ▼-0.175
Profitability
Return on equity ▼-0.074Return on assets ▼-0.005Return on invested capital -0.000Return on capital employed ▲+0.001Operating ROA ▲+0.055Income quality ▲+0.119Tax burden 0.000
Efficiency
Days sales outstanding ▼-44.458Days payables outstanding ▲+46.306Operating cycle ▼-44.458Cash conversion cycle ▼-90.764Capex / Sales ▲+0.842R&D / Sales ▲+6.321
Balance-sheet strength
Current ratio ▼-1.792Net debt / EBITDA ▲+0.033Working capital ▼-80754000.000Invested capital ▼-93112000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-97.9%EV / Sales ▼-77.5%EV / EBITDA ▲+95.7%EV / Op. cash flow ▲+32.528Earnings yield ▼-1.130
Profitability
Return on equity ▼-0.345Return on assets ▼-0.197Return on invested capital ▼-0.257Return on capital employed ▼-0.264Operating ROA ▼-0.108Income quality ▲+0.011Tax burden 0.000
Efficiency
Days sales outstanding ▼-6.398Days payables outstanding ▼-462.185Operating cycle ▼-6.398Cash conversion cycle ▲+455.787Capex / Sales ▼-0.012R&D / Sales ▲+12.365
Balance-sheet strength
Current ratio ▼-2.007Net debt / EBITDA ▼-0.337Working capital ▼-379495000.000Invested capital ▼-443210000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-01-31 | Daniel Goldman | Sale | $1,001 - $15,000 |
Recent news
- 2026-08-05 FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before recess, Congress'' August checklist and the Democratic Party''s direction after Tuesday''s primaries on ‘Mornings with Maria.
- 2026-08-03 Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on August 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 37,300 shares of the Company''s common stock at an exercise price per share of $2.45, which was the closing price per share of the Company''s common stock as reported by NASDAQ on July 31, 2026, and (ii) restricted stock units (RSUs) representing 45,300 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company''s Board of Directors and granted under the Company''s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
- 2026-07-09 Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
- 2026-07-06 Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company''s off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.
- 2026-07-06 Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company''s off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.
- 2026-07-01 Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the third quarter of 2026.
- 2026-06-24 Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They''ve reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself.
- 2026-06-15 Fate Therapeutics Appoints Laura Hamill to Board of Directors Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization
- 2026-06-15 Fate Therapeutics Appoints Laura Hamill to Board of Directors SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced the appointment of Laura Hamill to its Board of Directors.
- 2026-06-04 Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of rapid and sustained clinical improvement with favorable tolerability profile observed following treatment of systemic lupus erythematosus (SLE) patients with FT819 and less-intensive conditioning chemotherapy; a majority of evaluable patients on background glucocorticoids achieved either complete glucocorticoid discontinuation or guideline-based tapering targets FT819 demonstrated deep B-cell depletion with reconstitution of preferred less-differentiated state associated with a healthier repertoire of B cells; elimination of dominant B-cell clones in dose-dependent manner was seen while vaccination titers were maintained In preclinical studies, FT839 exhibited comprehensive elimination of activated immune cells in rheumatoid arthritis patient samples; activity accomplished while in allogeneic setting without the need for conditioning chemotherapy SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, presented data today featuring its off-the-shelf CAR T-cell programs FT819 and FT839 at the European Congress of Rheumatology (EULAR) annual meeting being held in London, UK, June 3-6, 2026. “The data presented for FT819 with less-intensive conditioning and off-the-shelf CAR T-cell therapy product candidate in SLE is truly exciting, and we are very pleased that our highly-differentiated therapeutic approach has the potential to transform autoimmune disease outcomes by supporting persistent reductions in cSLEDAI, PGA, FACIT-fatigue, and UPCr scores and promoting effective B-cell depletion with preferred subtype reconstitution while maintaining a distinctly favorable tolerability profile,” said Bob Valamehr, Ph.D.